Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R35NS097263)
Received: 1 June 2020
Accepted: 6 July 2020
First Online: 27 July 2020
: A.D.G. has served as a consultant for Aquinnah Pharmaceuticals, Prevail Therapeutics, and Third Rock Ventures, and is a scientific founder of Maze Therapeutics. S.A.L. is an academic founder of AstronauTx Ltd. B.A.B. is a co-founder of Annexon Biosciences Inc., a company working to make new drugs for treatment of neurological diseases. The remaining authors declare no competing interests.